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Abstract
The implementation of the 2013 world Health Organization Option B+ recommendations for Hiv treatment during 
pregnancy has helped drive significant progress in achieving universal treatment for pregnant and postpartum women 
in sub-Saharan Africa (SSA). Yet, critical research and implementation gaps exist in achieving the UNAiDS 90-90-90 
targets. To help guide researchers, programmers and policymakers in prioritising these areas, we undertook a comprehensive 
review of the progress, gaps and research needs to achieve the 90-90-90 targets for this population in the Option B+ 
era, including early infant Hiv diagnosis (eiD) for Hiv-exposed infants. Salient areas where progress has been achieved 
or where gaps remain include: (1) knowledge of Hiv status is higher among people with Hiv in southern and eastern 
Africa compared to western and central Africa (81% versus 48%, UNAiDS); (2) access to antiretroviral therapy (ART) 
for pregnant women has doubled in 22 of 42 SSA countries, but only six have achieved the second 90, and nearly a 
quarter of pregnant women initiating ART become lost to follow-up; (3) viral suppression data for this population are 
sparse (estimates range from 30% to 98% peripartum), with only half of women maintaining suppression through 12 
months postpartum; and (4) eiD rates range from 15% to 62%, with only three of 21 high-burden SSA countries testing 
>50% Hiv-exposed infants within the first 2 months of life. we have identified and outlined promising innovations and 
research designed to address these gaps and improve the health of pregnant and postpartum women living with Hiv 
and their infants.
Keywords: prevention of mother-to-child transmission, prevention of vertical transmission, Hiv, pregnancy, postpartum, sub-
Saharan Africa
Introduction
The expansion of Hiv care and treatment for pregnant and 
postpartum women in sub-Saharan Africa (SSA) exemplifies a 
significant achievement in the global Hiv response. in southern 
and eastern Africa, home to 50% of the Hiv population globally, 
antiretroviral therapy (ART) coverage for pregnant women has 
increased from 47% in 2010 to 93% in 2017 [1]. A variety of 
tools and evidence-based strategies have emerged to improve 
the health of pregnant and postpartum women with Hiv, encour-
aging optimism towards achieving the ambitious targets established 
by the Joint United Nations Programme on Hiv/AiDS (UNAiDS): 
that 90% of people living with Hiv (PLHiv) know their status, 
90% of diagnosed people are on ART, and 90% of those on ART 
are virally suppressed by 2020 [2,3]. Progress in the prevention 
of mother-to-child transmission (PMTCT) of Hiv has also been 
substantial. with adequate adherence, ART carries the potential 
to virtually eliminate the risk of vertical Hiv transmission for 
pregnant and breastfeeding women. At the country level, achiev-
ing ≥95% population-level ART coverage for pregnant women 
is a process indicator for national elimination of MTCT (defined 
as MTCT rates <5% in breastfeeding populations or <2% in 
non-breastfeeding populations) [4-8].
However, progress across SSA has not been uniform, and as our 
understanding of the Hiv epidemic has deepened, critical gaps 
have been identified, which will need to be addressed in order 
to achieve the 90-90-90 goals for pregnant and postpartum 
women. examples of these gaps include: (1) facility-based Hiv 
testing has been broadly implemented for pregnant women in 
much of southern and eastern Africa, but central and western 
Africa are lagging behind [9]; (2) from country to country, the 
proportions of pregnant women accessing ART vary considerably, 
with many still far from reaching the second 90, even as others 
have surpassed it [10]; (3) achieving and sustaining viral sup-
pression throughout pregnancy, delivery and the breastfeeding 
period remains a challenge in multiple countries [11,12], and as 
a result, there were still an estimated 180,000 new Hiv infections 
in children in 2017 [1]; and (4) for Hiv-exposed infants, gaps 
in early infant diagnosis remain substantial [13]. in this review, 
we summarise recent progress, remaining knowledge gaps, and 
identify the future research needed to achieve and eventually 
surpass the 90-90-90 targets for pregnant and postpartum women 
in SSA (Table 1).
First 90: knowledge of HIV status
Globally, an estimated 75% of all PLHiv knew their status in 
2017, and across many SSA countries, knowledge of Hiv status 
is higher among women of reproductive age (15–49 years) as 
compared to men [1]. Universal Hiv testing for pregnant women 
initiating facility-based antenatal care (ANC) has been broadly 
implemented in many regions in southern and eastern Africa, yet 
central and western Africa, where the healthcare delivery systems 
are weaker, have been slower to implement this approach [9]. 
Further, general knowledge of Hiv status among PLHiv in western 
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Table 1. Research priorities to achieve 90-90-90 for pregnant and 
postpartum women in sub-Saharan Africa
First 90
 • identify approaches to detecting acute Hiv infection in 
pregnancy and postpartum periods
 • Determine structural- and individual-level barriers to repeat 
testing in late pregnancy and breastfeeding periods
 • evaluate strategies to ensure universal uptake of antenatal 
services, including Hiv testing
 • Develop innovative testing approaches to identify Hiv-positive 
pregnant/postpartum women in lower Hiv-prevalence regions
Second 90
 • Further understand barriers to ART uptake and retention in 
care
 • Assess interventions to improve ART uptake and retention in 
care
 • explore optimal models of integrated Hiv and maternal and 
child health services
 • evaluate differentiated models of care for pregnant and 
postpartum women on ART
 • Develop strategies to identify and mitigate ART-associated 
adverse birth outcomes 
Third 90
 • Promote research, country and programme reporting of viral 
load outcomes during pregnancy and breastfeeding
 • evaluate interventions that promote sustained adherence to 
ART, focused on postpartum period
 • Determine optimal timing and frequency of viral load 
monitoring in pregnancy and postpartum
 • evaluate biomedical and behavioural approaches designed to 
achieve rapid viral suppression during pregnancy and 
breastfeeding
Early infant diagnosis of HIV for HIV-exposed infants
 • evaluate integrated approaches to ensure universal uptake of 
early infant diagnosis
 • Optimise retention, through the breastfeeding period, of 
exposed infants
 • establish best strategies to incorporate birth testing and 
point-of-care eiD technologies
 • Develop Hiv testing approaches for infants of women with 
acute infection during breastfeeding
and central Africa is considerably lower than other African regions 
– at 48%, as compared to 81% in southern and eastern Africa 
[1]. Stigma and discrimination, test kits stock outs, healthcare 
worker shortages and user fees all contribute to undermining 
achievement of the first 90 for pregnant and postpartum women 
[14]. in addition, as many as 20% of women in SSA are estimated 
to have no antenatal care, and thus miss antenatal Hiv testing 
entirely [15]. To complicate matters further, pregnancy and the 
perinatal period are associated with an increased risk of Hiv 
acquisition [16,17]. in a cohort of over 1300 pregnant women 
in western Kenya, followed through 9 months postpartum, Hiv 
incidence was 2.31 per 100 person-years [18]. Studies from 
Tanzania and Zambia [19] demonstrated similar results [20]. A 
critical testing gap also exists for sexually active adolescent girls, 
particularly in western and central African countries. For example, 
in Nigeria, 33% of adolescents (ages 10–19 years), as compared 
to 52% of adult women, reported being tested for Hiv during 
their last pregnancy [21,22].
Several evidence-based strategies exist to improve Hiv testing 
uptake among pregnant women, with fewer strategies specifically 
focused in the postpartum or breastfeeding periods. Universal, 
opt-out testing in ANC clinics has been highly successful in eastern 
and southern Africa. Repeat testing during pregnancy, and at 
least once during breastfeeding, is cost-effective, although it has 
been implemented with varying success [23,24]. Door-to-door 
testing by lay healthcare workers, and recent approaches inte-
grating immediate ART initiation with community testing, may 
improve knowledge of Hiv status pre-pregnancy, and identify 
pregnant women who have not enrolled in ANC [25,26]. Testing 
as part of home-based couples counselling may be particularly 
beneficial for women who are afraid of knowing their status and 
disclosing to their partner(s) [26]. Self-testing is an emerging 
strategy that may be particularly beneficial for sexually active 
adolescent girls [27-29]. increased knowledge of personal Hiv 
status among the general population using promising approaches, 
such as integration of Hiv testing within multi-disease health 
campaigns, is likely to increase the proportion of women who 
know their Hiv status prior to pregnancy and breastfeeding 
[30,31].
important research gaps exist that need to be filled in order to 
improve knowledge of Hiv status in pregnant and postpartum 
women. identification and assessment of innovative Hiv testing 
strategies that consider the lower Hiv prevalence are needed for 
west and central Africa. Furthermore, approaches to improving 
uptake of antenatal care in women with low ANC attendance, 
including community-based peer navigators or thoughtful engage-
ment of traditional birth attendants to promote Hiv testing, should 
be explored. Further work is needed to identify optimal timing 
and implementation of repeat Hiv testing for women, and to 
better understand structural and individual level barriers to repeat 
testing [32]. Testing strategies that take into account the unique 
developmental stage and challenges facing pregnant adolescents 
need to be identified and evaluated in order to increase testing 
uptake in this population.
Second 90: uptake of ART
The scale-up of world Health Organization (wHO) recommen-
dations, including Option B (ART for all women through pregnancy 
and breastfeeding) and Option B+ (lifelong ART for pregnant 
women), has yielded remarkable progress in ART coverage for 
pregnant and postpartum women in SSA (Figure 1). ART access 
for PMTCT more than doubled in 22 of 42 SSA countries with 
available UNAiDS Global AiDS Monitoring (GAM) data, and six 
countries (Botswana, Namibia, South Africa, Swaziland, Uganda 
and Zimbabwe) have surpassed the second 90 target for pregnant 
women as of 2016 [4,10]. Yet, wide variations in ART coverage 
exist within the continent, with fewer than 40% of Hiv-positive 
pregnant women accessing ART in Nigeria and Mali compared 
to over 95% in Botswana, South Africa and Uganda in 2016 
[10]. Furthermore, barriers to retention in care and maintenance 
on ART have surfaced as key obstacles to achieving the second 
90 in SSA [33-36]. Since the implementation of Option B+, 
pooled retention estimates across SSA suggest that one-in-four 
women become lost to follow-up within 6 months of ART initia-
tion [37], with women initiating ART during pregnancy up to 
five times more likely to become disengaged compared to women 
starting ART because of advanced Hiv disease [35]. Adverse 
birth outcomes as a result of in utero ART exposure are persistent 
concerns, as various studies have reported increased risk of preterm 
birth and low birth weight, which are themselves associated with 
increased newborn morbidity and mortality in resource-limited 
settings [5,38,39]. Protease inhibitors, and to a lesser extent 
nucleoside and non-nucleoside transcriptase inhibitors, are most 
often associated with these adverse birth outcomes. Of particular 
concern is a preliminary report of increased neural tube defects 
in women who conceive on the integrase inhibitor dolutegravir, 
which is a potent and well-tolerated antiretroviral agent, whose 
use is rapidly growing in SSA [40,41].
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A variety of evidence-based, scalable interventions have been 
described that could help reach the second 90 in SSA [42]. These 
interventions span the social, behavioural and structural aspects 
of PMTCT care at both the facility and community levels [43]. 
improved ART uptake and retention has been demonstrated with 
expert peer support and ‘mentor mothers’ [44,45], individual or 
group counselling sessions [45], and community health workers 
who provide supportive supervision, ART counselling and tracing 
of women who default from care [46-48]. Male partner involve-
ment has also been shown to improve maternal ART uptake [49-
51]. Behavioural interventions by way of text message or phone 
call appointment reminders (mHealth) have been effective in 
improving ART uptake and retention across multiple Hiv popula-
tions, and there is promising evidence of their feasibility and 
potential efficacy in the PMTCT population as well. economic 
incentives, such as conditional cash transfer [52] and disclosure 
support to partners [53] have been less well studied, but may 
provide additional retention benefits. Structurally, the integration 
of Hiv services into maternal and child health and postnatal 
services has played an important role in expanding capacity for 
ART coverage, and may improve retention in care compared to 
non-integrated services [54,55]. Combination interventions are 
also increasingly being examined to maximise gains in retention 
and maintenance on ART [42,56,57]. Finally, although many SSA 
countries have yet to implement national surveillance for ART-
related adverse birth outcomes, researchers in Botswana, through 
the Botswana-Harvard partnership (Tsepamo study), have estab-
lished a unique surveillance programme that has contributed key 
data to inform our understanding about the safety of ART for 
the mother and fetus [40,41].
Despite important progress, knowledge gaps persist concerning 
the optimal implementation strategies to achieve the second 90. 
Overall, the evidence for many of the aforementioned interven-
tions is weak and heterogeneous, with limited duration of effect. 
Further research is needed to: (1) identify the barriers to care; 
(2) study the impact of interventions on long-term retention; 
(3) determine successful integration and differentiated care models 
for PMTCT; and (4) evaluate strategies to optimise ART uptake 
while maximising safety. Failure to engage in antenatal and Hiv 
care threatens not only Hiv-exposed infants, but the health of 
women with Hiv and their partners.
identifying barriers to care is critical, including their relative sig-
nificance, and the optimal social and behavioural interventions 
to address them, particularly in terms of their cost-effectiveness 
and scalability for care programmes. Many studies have looked 
at the impact of interventions to improve adherence and reten-
tion for the period up to 12 months post-delivery; however, 
breastfeeding and PMTCT follow-up can last 18 months or longer 
in many cultures. Studying the impact of interventions through 
the conclusion of PMTCT follow-up, and through the transition 
back to an Hiv clinic for postpartum women, is vital to under-
standing their durability and true effect sizes.
On a structural level, integrated service delivery models that max-
imise efficiency and efficacy for stable PMTCT clients, including 
models of differentiated and decentralised ART delivery, and 
patients’ preferences for such models, need to be rigorously 
evaluated [58]. High-quality, large, population-based studies 
to better understand the factors that drive regional variations 
in ART coverage for pregnant and postpartum women in SSA will 
also help achieve the second 90 goals for them. Finally, questions 
remain concerning the timing of ART initiation, and the effects of 
established and novel ART regimens (e.g. dolutegravir) on adverse 
birth outcomes (e.g. stillbirth, preterm birth, growth restriction, 
congenital anomalies) and infant development [41,59-61].
Third 90: viral suppression
Achieving and maintaining viral suppression is urgent for pregnant 
and postpartum women in order to minimise vertical Hiv trans-
mission and maximise women’s health outcomes [62]. while routine 
viral load monitoring among PLHiv on ART is now recommended 
by wHO, scale-up has been slow. in a study focused on seven 
of the SSA countries, only one was performing at least one viral 
load on more than 85% of patients on ART (South Africa [91%]); 
two countries (Kenya [40%] and Namibia [23%]) tested fewer 
than 50% of patients on ART, and four countries (Côte d’ivoire 
[11%], Malawi [19%], Tanzania [9%], and Uganda [22%]) tested 
No data
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15–50%
50–89%
Non Sub-Saharan Africa
≥90%
No data
<0 PP
0–25 PP
25–50 PP
Non Sub-Saharan Africa
PP : Percentage points
50–76 PP
2010 2016 2010–2016 change in coverage
Figure 1. Antiretroviral therapy coverage for pregnant women living with Hiv in sub-Saharan Africa, 2010–2016 (excluding single-dose nevirapine). Data from [10]
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fewer than 25% [63]. Further, recognition of pregnant and 
postpartum women as a priority population for monitoring and 
rapid intervention in the setting of virological failure is lacking 
[63-65]. As a result, literature on viral suppression among preg-
nant and breastfeeding women in SSA is sparse and frequently 
comes from research studies rather than routine care programmes. 
Additionally, several of these studies were conducted in settings 
and during time periods when universal ART was not the standard 
of care, and thus have a mixed population of women who are 
on ART as well as those on PMTCT prophylaxis [66].
Available data show viral suppression rates at delivery or imme-
diately postpartum have ranged from 30% to 98% in different 
SSA settings, and are dependent on the viral load threshold used 
(Table 2). Keeping women engaged in care and optimally adher-
ent to ART following delivery is a well-known challenge, and 
undermines sustained viral suppression[35,48]. in Malawi, although 
70% of women starting ART during pregnancy and breastfeeding 
had adequate adherence (defined as having ART drugs available 
≥90% of days between clinic visits), only one-third of them 
maintained adequate adherence over 2 years of treatment [67]. 
Similarly, among women who became pregnant after initiating 
ART in South Africa, the risk of non-adherence was nearly 50% 
higher during the postpartum period compared to the non-
pregnant period [68,69]. Further, even among those who are 
retained in care, optimal viral control (>90% with vL <50 copies/
mL) in the postpartum period is rarely achieved. in Nigeria, only 
58% of women attained suppression (<20 copies/mL) at 6 months 
postpartum [70]. while in a follow-up study of 523 previously 
virally suppressed (<50 copies/mL) women in Cape Town, only 
70% were able to maintain viral suppression through 12 months 
postpartum [11]. The most promising and longest follow-up comes 
from the PROMOTe trial in Uganda, in which approximately 90% 
of women had vL <400 copies/mL at 24 months postpartum 
[71]; and 5 years later, among a random sample of 200 partici-
pants, 90% had maintained viral suppression [72].
evidenced-based approaches to address the main drivers of viro-
logical failure are being elucidated. while in many settings, data 
are lacking or not well utilised to address gaps in the third 90, 
South Africa’s rapid and successful scale-up of PMTCT has been 
attributed to the use of data-driven continuous quality improve-
ment interventions that identify problems as they emerge, and 
empowers front-line staff to create local solutions [77,78]. This 
strategy is currently being fully evaluated in a cluster randomised 
trial focused on women initiating ART in pregnancy or during 
breastfeeding in the Democratic Republic of Congo [57]. A large 
number of studies have identified that non-adherence in preg-
nancy and the postpartum period is multifactorial, and may be 
driven by individual-level and biomedical issues, such as ART 
toxicity, stigma, mental health, ART toxicity and comorbidities, 
and structural issues related to healthcare worker attitudes and 
the availability of supportive services [11,66,72-74,79-84]. Thus, 
combination strategies that address these challenges are needed. 
Several studies are currently evaluating behavioural, peer naviga-
tor and mHealth interventions that may prove successful in attain-
ing and maintaining viral suppression for pregnant and postpartum 
women [85,86].
in order to reach the third 90 for pregnant and postpartum women, 
the lack of data highlighted above, especially data from routine 
PMTCT implementation at programme and country level, will 
need to be addressed. Additionally, there is need for evidence-
based interventions that improve engagement in care and adher-
ence on ART among pregnant and breastfeeding women, and 
target previously identified modifiable predictors of viral sup-
pression in this population. in order to achieve the third 90 for 
pregnant and postpartum women, a research agenda targeted 
on addressing sustained adherence is vital. Additional research 
should address the optimal timing and frequency of vL monitor-
ing in pregnant and postpartum women and biomedical and 
behavioural interventions that rapidly achieve suppression in 
women with viremia.
Early infant diagnosis for HIV-exposed infants
Over 80% of newly infected children acquire their Hiv infection 
through MTCT, yet fewer than 50% of infants exposed to Hiv 
are tested at 6 weeks of age, and up to 45% are lost after initial 
testing [14,48]. eiD is the crucial first step in addressing the 
alarmingly high mortality rate for infants infected with Hiv, and 
is intricately linked with 90-90-90 goals for pregnant and post-
partum women [87]. Some countries in SSA have made significant 
progress scaling-up eiD testing; in a report on six SSA countries 
(Cote d’ivoire, Democratic Republic of Congo, Malawi, South 
Africa, Uganda and Zambia) it was noted that the total number 
of eiD tests performed on Hiv-exposed infants significantly 
increased between 2011 and 2015, but testing before 6 weeks 
of age was poor, ranging between 15% and 62% [88]. in 2016, 
among the 21 UNAiDS-designated high-burden countries (all of 
which are in SSA) (90), only three – South Africa, Swaziland, 
and Zimbabwe – managed to test over 50% of exposed infants 
within the first 2 months of life [14,89]. even when infants are 
tested, turn-around time for test results is so exceptionally long 
that caregivers may never receive the results [90].
Multiple strategies are gaining evidence of effectiveness in improv-
ing the first 90 for exposed infants in SSA. South Africa is the 
first high-burden country to introduce routine birth testing for 
exposed infants, and has achieved greater than 90% coverage. 
Complexities of neonatal Hiv treatment, and high rates of early 
losses to follow-up after birth testing, remain concerns for the 
introduction of birth testing on a wide scale [91,92]. Point-of-
care diagnostics may also be a promising new strategy that avoids 
the challenges associated with sample transport to centralised 
laboratories, and facilitates early intervention for positive results 
[93,94]. mHealth innovations, such as returning test results via 
short text message (SMS), electronic tracking systems and national 
web-based result dashboards, such as those being used in Kenya 
and South Africa, may support improved uptake as well as efficient 
return of results to providers and caregivers [95-97]. integration 
of maternal and child health services, and psychosocial support 
through peer or community interventions, supports eiD and reten-
tion of both mothers and exposed infants [49,54,98-101].
Further research into testing strategies that maximise uptake and 
facilitate early ART for infected infants are needed. How and 
where to integrate accurate point-of-care technologies into national 
eiD algorithms, including as testing at birth, need to be deter-
mined. Strategies for integrating surveillance for acute Hiv infection 
in pregnant and breastfeeding women with eiD for infants should 
be explored. Further evidence is needed for cost-effective psy-
chosocial support models that encourage Hiv testing among 
exposed infants.
Conclusion
Despite considerable expansion of quality PMTCT services, and 
widespread uptake of Option B+, most countries in SSA have not 
achieved UNAiDS 90-90-90 targets for pregnant and postpartum 
women. A targeted research agenda as outlined in this paper is 
an important next step in reaching these critical goals, in order 
to achieve the elimination of vertical Hiv transmission and ensure 
the health and well-being of women and their families.
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Table 2. Summary of studies on the prevalence of viral suppression in sub-Saharan Africa
Author Enrolment 
period
Region Design ART eligibility 
and naivety 
status
Timing of 
enrolment 
Analytical 
sample
Viral load 
threshold 
(copies/mL)
Timing of VL 
sampling
Prevalence 
(%)
Chagomerana 
et al. [73] 
Jun 2015– 
Nov 2016
Lilongwe, 
Malawi
Prospective 
cohort 
ART-naïve and 
experienced 
First ANC of 
current 
pregnancy
252 <1000 Delivery 84
<40 Delivery 69
Chetty et al. 
[12]
2010–2015 Rural 
KwaZulu-
Natal, 
South 
Africa
Prospective 
cohort 
ART-experienced 
(at least 6 months)
Pregnancy, 
during first 
ANC visit
1425 <1000 Pre-pregnancy 89
Pregnancy 85
6 months postpartum 84
12 months postpartum 82
25 months postpartum 83
<50 Pre-pregnancy 82
Pregnancy 77
6 months postpartum 77
12 months postpartum 76
25 months postpartum 76
Cohan  
et al.[71]
Dec 2009– 
Mar 2013
District 
Tororo, 
Uganda
Randomized 
control trial 
(test efficacy 
of efavirenz 
vs lopinavir/
ritonavir)
ART naïve-eligible Pregnant, 
12-28 
weeks
389 <400 Delivery (efavirenz 
arm)
98
Delivery (lopinavir/
ritonavir arm)
86
48 weeks postpartum 
(efavirenz arm)
91
48 weeks postpartum 
(lopinavir/ritonavir 
arm)
88
Gill et al. 
[74]
Apr 2013– 
Jan 2014
Kigali, 
Rwanda
Prospective 
cohort 
ART-naïve and 
experienced 
Third 
trimester of 
pregnancy 
and up to  
2 weeks 
post-partum
608 <20 ≤4 months under ART 30
<20 >4 months under ART 66
<20 >12 months under 
ART
66
<1000 >12 months under 
ART
90
Hosseinipour 
et al. [75]
Jan 2003– 
Mar 2017
Central and 
southern 
Malawi
Randomized 
control trial
ART naïve-eligible Pregnancy 
or post- 
partum
1269 <1000 6 months post 
enrollment
84
Koss et al. 
[72]
Mar 2015– 
Sept 2015
District 
Tororo, 
Uganda
Cross-
sectional
ART naïve-eligible Pregnancy, 
12-28 
weeks 
150 <400 Postpartum 90
Myer et al. 
[76]
Apr 2013– 
May 2014
Cape Town, 
South 
Africa
Retrospective 
cohort 
ART naïve-eligible First ANC of 
current 
pregnancy
620 ≤1000 Delivery 91
≤50 Delivery 73
Myer et al. 
[11]
Apr 2013– 
May 2014
Cape Town, 
South 
Africa
Prospective 
cohort 
women who 
initiated ART 
during pregnancy 
and achieved 
initial viral 
suppression during 
follow-up
First ANC of 
current 
pregnancy
523 sustained 
viral load 
<50 during 
follow-up
Across follow-up 
(median 322 days) 
during the postpartum 
period: 7 days, 6 
weeks, 3 months, 6 
months, 9 months, 
and 12 months
70
Sam-Agudu 
et al. [45]
Apr 2014– 
Sept 2015
Federal 
Capital 
Territory 
and 
Nasarawa 
states, 
North-
central 
Nigeria
Prospective 
cohort 
ART-naïve and 
experienced 
Pregnancy, 
mixed 
gestational 
ages 
497 <20 Postpartum 58
ANC: antenatal clinic; cp: copies; vL: viral load.
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